Molecular Partners AG (MOLN.SW) SIX

2.81

-0.09(-3.10%)

Updated at September 08 05:31PM

Currency In CHF

Molecular Partners AG

Address

Wagistrasse 14

Schlieren, 8952

Switzerland

Phone

41 44 755 77 00

Sector

Healthcare

Industry

Biotechnology

Employees

158

First IPO Date

March 03, 2015

Key Executives

NameTitlePayYear Born
Dr. Patrick Amstutz Ph.D.Co-Founder, Chief Executive Officer, Member of Management Board & Director652,0001975
Mr. Michael PitznerGeneral Counsel, Compliance Officer, Senior Vice President Legal & Business Development0N/A
Dr. Pamela A. Trail Ph.D.Strategic Consultant01956
Mr. Daniel Steiner Ph.D.Senior Vice President of Research & Technology0N/A
Mr. Seth D. LewisSenior Vice President of Investor Relations, Communications & Strategy0N/A
Mr. Robert HendriksSenior Vice President of Finance0N/A
Dr. Michael Tobias Stumpp Ph.D.Co-Founder, Executive Vice President of Projects & Member of Management Board01972
Ms. Renate GloggnerExecutive Vice President of People & Community and Member of Management Board01970
Dr. Philippe Legenne M.B.A., M.D.Chief Medical Officer & Member of the Management Board01966
Mr. Alexander ZurcherChief Operating Officer & Member of Management Board01975

Description

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.